Ancora Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Ancora Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,650	Closed	-$865	–	1874
2023 Q2	$865	Hold	7,650	–	–	﹤0.01%	1581
2023 Q1	$1.26K	Hold	7,650	–	–	﹤0.01%	1599
2022 Q4	$1K	Sell	7,650 -7,000	-48%	-$915	﹤0.01%	1770
2022 Q3	$1K	Hold	14,650	–	–	﹤0.01%	2027
2022 Q2	$1K	Hold	14,650	–	–	﹤0.01%	2220
2022 Q1	$1K	Sell	14,650 -120	-0.8%	-$8	﹤0.01%	2384
2021 Q4	$1K	Hold	14,770	–	–	﹤0.01%	2358
2021 Q3	$1K	Buy	14,770 +120	+0.8%	+$8	﹤0.01%	2192
2021 Q2	$1K	Hold	14,650	–	–	﹤0.01%	1929
2021 Q1	$1K	Buy	+14,650	New	+$1K	﹤0.01%	1716

Other funds holding PVCT

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

Atlas Wealth Cincinnati, Ohio $334M AUM 11.57% 1-Year Est. Return

LIA

LBMC Investment Advisors Brentwood, Tennessee $1.64B AUM 15.26% 1-Year Est. Return

ACM

Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return

Ancora Advisors's PVCT Position: Q3 2023 in Review

Ancora Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2023, closing a stake of 7,650 shares — an estimated $865 sold.

Ancora Advisors first reported a position in PVCT in Q1 2021 and held it in 10 quarters. The position peaked at $1.26K in Q1 2023. 6 funds tracked by Wall St. Rank hold PVCT as of Q3 2023.

Ancora Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2023 after selling out during the quarter.
Ancora Advisors sold 7,650 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2023, an estimated $865.
Ancora Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q1 2021 and held it in 10 quarters.
Ancora Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $1.26K in Q1 2023.
6 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2023.

Based on Ancora Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.